Volume 35, Issue 1, March 2024

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2024;35(1):150-5
New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature
Authors Information

1Greek Rheumatology Society and Professional Association of Rheumatologists, Private Practice, Greece

2Gastroenterology Department, Alexandra General Hospital, Athens, Greece


M Krikelis, E Papathanasiou, G Leonidakis, P Pardalis, S Michopoulos, E Zampeli

  1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015 Sep 5;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7.
  2. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis 2020 Mar 13;14(3):351-60. doi: 10.1093/ecco-jcc/jjz152.
  3. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 2018 Feb;29(1):13-8. doi: 10.1080/09546634.2017.1329511.
  4. Orzan OA, Țieranu CG, Olteanu AO, Dorobanțu AM, Cojocaru A, Mihai MM, et al. An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics 2023 Aug 21;15(8):2171. doi: 10.3390/pharmaceutics15082171.
  5. Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021 Mar 30;12:622934. doi: 10.3389/fimmu.2021.622934.
  6. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004 Jan;110(1):55-62. doi: 10.1016/j.clim.2003.09.013.
  7. Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS One 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781.
  8. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668.
  9. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity 2015 Oct 20;43(4):727-38. doi: 10.1016/j.immuni.2015.09.003.
  10. Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol 2023 Mar 23;14:1124628. doi: 10.3389/fphar.2023.1124628.
  11. Truong SL, Chin J, Liew DFL, Zahir SF, Ryan EG, Rubel D, et al. Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. Rheumatol Ther 2021 Dec;8(4):1603-1616. doi: 10.1007/s40744-021-00360-6.
  12. Orrell KA, Murphrey M, Kelm RC, Lee HH, Pease DR, Laumann AE, et al. Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program. J Am Acad Dermatol 2018 Oct;79(4):777-778. doi: 10.1016/j.jaad.2018.06.024.
  13. Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019 May 14;25(18):2162-2176. doi: 10.3748/wjg.v25.i18.2162.
  14. Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020 Aug;16(8):415-433. doi: 10.1038/s41584-020-0454-9.
  15. Zioga N, Kogias D, Lampropoulou V, Kafalis N, Papagoras C. Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology. Mediterr J Rheumatol 2022 Apr 15;33(Suppl 1):126-36. doi: 10.31138/mjr.33.1.126.
  16. Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020 Sep;79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927.
  17. Machado PM, Deodhar A. Treat-to-target in axial spondyloarthritis: gold standard or fools' gold? Curr Opin Rheumatol 2019 Jul;31(4):344-8. doi: 10.1097/BOR.0000000000000625.